Window-of-opportunity trials are a path to screen effective agents and optimize dose in breast cancer risk reduction.
We review the scientific evidence regarding the utility of window-of-opportunity trials to screen effective agents and optimize dose for successful risk reduction/interception of breast cancer.
Low-dose tamoxifen was evaluated in a window-of-opportunity trial and then validated in a phase-III trial.
We are now studying similar activity with low-dose exemestane.
